Pfizer Issues Top-Line Results from Potherpetic Neuralgia, Painful Diabetic Peripheral Neuropathy Studies in China: PDPN Phase 3 Did Not Hit Endpoint, PHN Phase 4 Study Met Primary Endpoint
August 12, 2014 at 17:04 PM EDT
Pfizer Inc. (NYSE: PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica^® ...
